Omixon Founder, Attila Bérces Returns as CEO, Aims to Roll-Out New Products

20/04/2020

We are happy to announce that Omixon’s founder and chairman Dr. Attila Bérces returns as CEO. Outgoing CEO Dr. Peter Meintjes led the early commercialization of Omixon’s flagship product Holotype HLA since 2014 before stepping into the CEO role in 2017. In concert between the incoming and outgoing CEOs,...

Update Regarding our Operations during COVID-19

20/04/2020

Dear Customers, Due to the SARS-CoV-2 outbreak, we have already notified you about changes in our operations. Please see below further amendments we would like to inform you about: Our Global Logistics Team continues all activities, but considering the service quality and transit unpredictability of all freight companies, Omixon decided...

The New, Blazing Fast HLA Twin v4.2

31/03/2020

Two month ago, Omixon announced the release of the newest HLA Twin version which featured significant improvements in the software’s performance and responsiveness that facilitated the result review process and overall analysis workflow. Omixon team has been working on additional and even more significant improvements in HLA Twin. This...

How Genetic Variation in the Immune System Predicts COVID-19 Disease Outcome

23/03/2020

Authors: Csaba Pal, Mate Manczinger, Attila Berces As we all know, the COVID-19 infectious disease caused by the SARS-CoV2 virus has spread globally. It is a significant and urgent medical threat with serious implications on our personal life and global economy. Therefore, it is of paramount importance to identify...

Webinar – HLA Typing Uses in Research. How is HLA Explore Used to Facilitate it?

20/03/2020

Join us for a Webinar on Tuesday, April 7 with Efi Melista (Head of Product, Omixon) who will be talking about the uses of HLA typing in research and population studies, and how Omixon’s HLA Explore can facilitate it. Examples in disease associations, pharmacogenetics, drug sensitivities and overall population...